REMARKS

The Amendments

Claims 1 and 7 are amended to replace the chemical alphanumeric identifier with the full chemical name or common name. The amendment is supported by the common knowledge of these synonymous names in the art. In addition to the previous support provided, additional support therefore is in the attached literature references. The amendments do not narrow the broadest scope of the claims.

It is submitted that the above amendments would put the application in condition for allowance or materially reduce or simplify the issues for appeal since they render moot the 35 U.S.C. §112, second paragraph rejection. The amendments do not raise new issues or present new matter and do not present additional claims. The amendments have been made to render the 35 U.S.C. §112, second paragraph, rejection moot. As discussed below, they were not believed to be necessary but are made to advance prosecution and have no substantive effect on the meaning of the claims. Thus, they were not earlier presented. Accordingly, it is submitted that the requested amendments should be entered.

Applicants reserve the right to file one or more continuing and/or divisional applications directed to any subject matter disclosed in the application which has been canceled by any of the above amendments.

The Rejection under 35 U.S.C. §112, second paragraph

The rejection of claims 1, 2, 4, 5, 7-11, 13, 19-38, 43 and 44 under 35 U.S.C. §112, second paragraph, is respectfully traversed.

Although applicants remain of the opinion that the previously recited identifiers of the specific PDE-IV inhibitors were well-defined, permanent and would have been known to one

of ordinary skill in the art, they have been replaced with either the chemical name or the common name by which they are otherwise known in the art. Thus, it is believed that the rejection is rendered moot and should be withdrawn.

The Rejection under 35 U.S.C. §103

The rejection of claims 1, 2, 4, 5, 7-11, 13, 19-38, 43 and 44 under 35 U.S.C. §103, as being obvious over Knowles (WO 03/011274) in view of Meissner (U.S. Patent No. 6,706,726) further in view of Hill (U.S. Patent No. 6,060,069) is respectfully traversed.

Applicants respectfully disagree that tiotropium, disclosed in Knowles, and applicants' compound 1 are of such similar structure that one of ordinary skill in the art would consider them to have the same or similar properties and be interchangeable. Referring to the formulae shown on page 9 of the Office Action, it is seen that there are five significant structural differences between these compounds:

- 1) the functional -OH group in tiotropium is replaced with a methyl group,
- 2) & 3) each of two 5-membered rings are replaced with 6-membered rings, and
- 4) & 5) in each of these two rings, the sulfur hetero group is removed such that heterocyclic rings are not provided.

There is no basis on the record to assume that such significant changes would not effect the properties of the compound and that these compounds would be interchangeably useful. To the contrary, tiotropium was known in the art before the Meissner patent was obtained and Meissner obtained the patent with claims covering compounds of formula I in view of this knowledge. Thus, a determination was made that compounds, such as of formula I, particularly with two phenyl groups, were patentably distinct over compounds such as tiotropium, having two thiophene groups. In any event, the number of structural differences,

on its face, is such that no presumption can be made that the compounds would have the same or similar properties. Such presumptions, in previous case law, were only made where the structures were adjacent homologs, such as methyl to ethyl. That is certainly not the case here. There is no legal basis to make such presumption where the structures have multiple and significant distinctions as here, i.e., replacing -OH with methyl and replacing each of two thiophene rings with phenyl rings.

The argument in the Office Action that tiotropium is closer in structure to applicants' formula 1 than the other compounds more specifically pointed out by Knowles supports substituting applicants' formula 1 compound as the anticholinergic in Knowles is not convincing. Even if it were true that tiotropium is closer to formula 1 than the other Knowles compounds (which is not admitted), this in no way supports that tiotropium is sufficiently closely similar to applicants' formula 1 compound that one of ordinary skill in the art would expect them to have the same or similar properties and be interchangeable.

Furthermore, Knowles only mentions tiotropium in a long list of other compounds and does not specifically direct one of ordinary skill in the art to select this compound over the other ones. To the contrary, Knowles directs one of ordinary skill in the art towards other compounds which are even more structurally distinct from applicants' formula 1; see, e.g., page 4, line 28, to page 5, line 31, and applicants' previous Reply (which is incorporated by reference herein). Thus, rather than suggesting replacement of its compounds with the Meissner compounds, Knowles directs one of ordinary skill in the art towards selection of the compounds which are alleged in the Office Action to be even more structurally distinct. In view of these teachings in Knowles, one of ordinary skill in the art would be directed away from compounds of applicants' formula 1, rather than towards them.

Additionally, Meissner further directs one of ordinary skill in the art away from interchanging such compounds and away from an expectation that such compounds would

exhibit the same or similar properties. Meissner refers to compounds of the type disclosed as anticholinergics in Knowles in its Background section (col. 1, line 33, to col. 2, line 26) and discloses that such compounds are deficient in meeting the requirements desired for the Meissner invention. Thus, Meissner's invention is directed to its structurally distinct compounds with distinct properties. The art thus supports an expectation of distinct properties for these compounds, rather than the same or similar properties.

Additionally, Knowles teaches that a specific type of anticholinergic is desired which has a certain M₁ and M₂ receptor antagonist activity; see paragraph bridging pages 4-5 of Knowles. Meissner provides no disclosure either way as to whether its compounds possess such antagonist activity. Thus, whether or not the compounds actually possess such activity, the failure of Meissner to teach such activity further detracts from any reasonable expectation of success by one of ordinary skill in the art in substituting the Meissner compounds, particularly selecting the specific compound of Example 1, into the Knowles compositions. This argument was made by applicants in their previous Reply but was not addressed in the Final action. Applicants thus reemphasize this argument and urge full consideration.

Applicants therefore urge that the cited references are directly contrary to the presumption which is made as the basis for the rejection, i.e., that the Meissner anticholinergies could be substituted for the Knowles anticholinergies with the expectation that the same or similar properties would be obtained.

Further directing one of ordinary skill in the art away from applicants' invention is the fact that Meissner does not suggest the use of its anticholinergics of formula 1 together with PDE-4 inhibitors. Also, Knowles does not direct one of ordinary skill in the art to select the particular PDE-4 inhibitors recited in the instant claims. Knowles, instead, particularly directs one of ordinary skill in the art towards those having a selective activity, specifically cilomilast or Ariflo[®]; see, e.g., page 3, line 25, through to page 5, line 31.

In view of all of the above, applicants strongly urge that the cited prior art does not provide a reasonable suggestion to one of ordinary skill in the art to make the particular combination of a compound of formula 1 of the instant claims together with a specific PDE-4 inhibitor, as recited in claim 1. To the contrary, the teachings of the references considered as a whole would have pointed one of ordinary skill in the art away from making such specific combination. Thus, it is urged that the combined teachings of Knowles and Meissner fail to suggest the claimed invention to one of ordinary skill in the art.

Hill was relied upon in the Office Action for suggesting certain dependent claim embodiments regarding particular excipients in the compositions. Hill provides no suggestions to make up for the deficiencies of the combination of Knowles and Meissner discussed above. Hill provides no suggestion of combining a compound of Meissner's formula 1 as an anticholinergic in the PDE-4 inhibitor compositions of Knowles. Therefore, while applicants reserve the right to discuss the distinction of the combined teachings of Hill for such dependent claim features, such discussion is not believed to be necessary at this time to establish nonobviousness.

For all of the above reasons, it is respectfully submitted that the combined teachings of Knowles, Meissner and Hill fail to suggest the claimed invention to one of ordinary skill in the art. Thus, the rejection under 35 U.S.C. §103 should be withdrawn.

The Provisional Obviousness-type Double Patenting Rejections

The provisional obviousness-type double patenting rejection of claims 1, 2, 4, 5, 7 and 43 over claims 1-13 of US Ser. No. 10/613,783 in view of claims 1-8, 11 and 21-23 of U.S. Patent No. 6,706,726 is overcome by the terminal disclaimer filed herewith.

It is submitted that the application is in condition for allowance. But the Examiner is kindly invited to contact the undersigned to discuss any unresolved matters.

Respectfully submitted,

John A. Sopp, Reg. No. 33,103 Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza 1, Suite 1400 2200 Clarendon Boulevard Arlington, Virginia 22201 Telephone: (703) 243-6333 Facsimile: (703) 243-6410

Attorney Docket No.: BIC-1364

Date: March 22, 2007

JAS:cak